logo-loader
viewImmuPharma PLC

ImmuPharma raises £1.5mln to expand R&D programmes

The funds have been raised through share subscriptions from chief scientific officer Robert Zimmer as well as significant shareholder Lanstead Capital

ImmuPharma PLC - ImmuPharma raises £1.5mln to expand R&D programmes

ImmuPharma PLC (LON:IMM) has raised £1.5mln from a share subscription to fund an expansion of its research & development (R&D) programmes.

The drug developer said it has raised the funds through the issue of 15mln new shares at a price of 10p each, a 6.5% discount to its closing price last Friday.

READ: Incanthera debuts on Nex Exchange and starts partner search for novel cancer treatment

The offering comprises a £200,000 share subscription by the company’s president and chief scientific officer Robert Zimmer, as well as a £1.3mln one from Lanstead Capital, an institutional investor and significant shareholder in the group.

The cash will be used to boost ImmuPharma’s R&D pipeline which now includes four therapy areas.

The company is strengthening its advisory team for a phase III trial of its Lupuzor lupus treatment and has also planned a proof of concept study for Lupuzor in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

ImmuPharma is also focusing on 3 anti-infectives, anti-viral, anti-fungal and anti-bacterial, as well as a new BioGlucagon product, a rescue therapy for low sugar events in diabetes, which has a potential market launch date in 2022.

"We believe that this latest investment from Lanstead is a strong endorsement of ImmuPharma and in support of their own carefully developed investment strategy of only supporting companies and technology platforms which have substantial future accretive opportunities”, ImmuPharma chairman Tim McCarthy said in a statement.

"The proceeds from these investments by Dr Zimmer and Lanstead, together with existing cash resources, will support the significant expansion of our R&D pipeline. We look forward to continuing our long and beneficial relationship with Lanstead which ultimately is focused on creating greater value for shareholders over the medium and long term", he added.

ImmuPharma shares rose 1% to 10.8p in early trading on Monday.

Quick facts: ImmuPharma PLC

Price: 16.1 GBX

AIM:IMM
Market: AIM
Market Cap: £29.46 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 down as Lloyd's of London expects claims to be...

Headlines from the Proactive UK newsroom. The FTSE 100 opened lower on fears that a second wave of coronavirus infections is coming after upticks in Germany, China and South Korea. The blue chip index shed 76 points at 5,827 in morning trading. Hargreaves Lansdown PLC (LON:HL.) has vowed...

1 week, 5 days ago

2 min read